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Abstract
Background: Global resurgence of dengue virus infections in many of the tropical and subtropical countries is a
major concern. Therefore, there is an urgent need for the development of successful drugs that are both
economical and offer a long-lasting protection. The viral NS2B-NS3 serine protease (NS2B-NS3pro) is a promising
target for the development of drug-like inhibitors, which are not available at the moment. In this study, we report
retrocyclin-1 (RC-1) production in E. coli as a recombinant peptide to test against dengue NS2B-NS3pro.
Methods: Dengue NS2B-NS3pro was produced as a recombinant single chain protein in E. coli and purified by
Ni+ affinity chromatography. The RC-1 peptide was produced in E. coli and the tri-disulphide bonds were reformed
in a diluted alkaline environment. Protease assay was performed using a fluorogenic peptide substrate and
measured by fluorescence spectrometry. Real-time PCR was used for quantification of dengue serotype 2 (DENV-2)
viral RNA produced in Vero cells.
Results: The RC-1 peptide inhibited the activity of recombinant NS2B-NS3pro with different values at 50%
inhibitory concentration (IC50) which are temperature dependent (28°C, 46.1 ± 1.7 μM; 37°C, 21.4 ± 1.6 μM; 40°C,
14.1 ± 1.2 μM). The presence of RC-1 significantly reduced viral replication in Vero cells infected with DENV-2 at
simultaneous treatment after 48 hrs (70%) and 75 hrs (85%). Furthermore, moderate reduction in viral replication
was observed at pre-treatment mode after 48 hrs (40%) and 72 hrs (38%) and post-treatment at 48 hrs (30%) and
72 hrs (45%).
Conclusion: Recombinant RC-1 inhibits DENV-2 replication in Vero cells by interfering with the activity of its serine
protease. Thus, we propose that recombinant RC-1 is a potent, cost-effective dengue virus inhibitor. Therefore, it is
suitable to consider RC-1 as a new candidate for drug development against dengue infection.
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Background
Dengue is an acute febrile viral disease with hundreds of
millions of infections occurring each year and more than
half of the world population are now at risk [1]. The
virus uses host cell ribosomes to translate its genomic
RNA to full length precursor polyprotein. Subsequently,
proteolytic cleavage of the polyprotein results in for-
mation of structural and non-structural proteins [2]. It
has been found that one of the most important non-
structural proteins is the NS3 protein. It has a trypsin-
like serine protease domain (NS3pro) located within the
N-terminal 180 amino acid residues [3,4]. However, the
activity of NS3pro depends on the interaction with its
cofactor NS2B (47 amino acids) to form NS2B-NS3pro
complex [5]. The importance of NS2B-NS3pro comes
from its ability to cleave at various regions in the viral
polyprotein [6-11]. It has been found that the disruption
of NS2B-NS3pro function inhibits viral replication [12].
Therefore, the NS2B-NS3pro is considered as a potential
target for antiviral drug design [13].
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At present, there are neither vaccines nor other treat-
ments available to prevent or cure this disease [14]. These
facts emphasize the need for a better understanding of the
mechanism of viral infection in order to combat this di-
sease. Recently, computational studies indicated that di-
sulphide cyclic peptides have potential to inhibit dengue
NS2B-NS3pro [15,16]. In this study, our aim was to inves-
tigate the potential inhibition of retrocylin-1 (RC-1), a
disulphide cyclic peptide, against dengue NS2B-NS3pro.
It has been known that RC-1 (GICRCICGRGICRCICGR)
is one of theta-defensins analogues which are circular,
cationic, tri-disulphide bonded peptides with beta–sheet
structure that can protect human peripheral blood lym-
phocytes from infection by HIV-1 strains [17]. This pep-
tide is encoded in the human genome by a theta-defensins
pseudogene [18]. However, it has only been found to play
important roles in the innate host defense in the white
blood cells of macaques, baboons and orang-utans [19,20].
Recent attempts have been made to confirm that human
cells have the ability to produce correctly folded retrocy-
clins using aminoglycosides to read-through the prema-
ture termination codon found in the mRNA transcripts
[21]. In our study, we successfully produced RC-1 in E.
coli as a recombinant peptide. The soluble recombinant
peptide was tagged with six histidine residues for metal
column purification. To reform tri-disulphide bonds in
the correct positions, the mis-folded peptide was refolded
in alkaline and diluted environment. Recombinant RC-1
exhibited significant inhibitory potential against dengue
NS2B-NS3pro and reduced viral replication in Vero cells.
We propose that the recombinant RC-1 could be consi-
dered as a candidate therapeutic peptide against dengue
virus infection.
Methods
Mosquito cell lines C6/36 was expanded to 80% conflu-
ence and infected with DENV-2 viruses (Isolate D2MY04-
32618) and incubated at 32°C for 3 days. To amplify the
cDNA fragment of NS2B-NS3pro sequence, DENV-2 in-
fected cells were harvested and viral RNA was extracted
using viral RNA Extraction Kit (Promega, USA) based on
to the manufacturer’s instructions. The cDNA fragment of
NS2B-NS3pro was generated using the NS2BF (5’-ATA
CTGAGGATCCGCCGATTTGGAACTG-3’) and NS3R
(5’-ATTGATCAAGCTTAAGCTTCAATTTTCT-3’) which
was then used as template to amplify NS2B (amino




To produce a single chain NS2B (G4-T-G4) NS3pro, the
NS2B fragments were amplified separately by PCR using
the primer pairs NS2BF and NS2BlikR (5’-ATACTGAG
GATCCGCCGATTTGGAACTG-3’, 5-ACCTACTAGG
TACCTCCTCCACCCAGTGTCTGTTCTTC-3’) while
NS3pro was amplified using NS3likF and NS3R primers
(5-ATCTATAGGTACCGGCGGTGGAGGTGCTGGAG-
TATTGTGG-3’, 5’-AGCATAAGCTTAAGCTTCAATTT
TCT-3’). The linker sequence and KpnI restriction sites
were added to NS2BlikR and NS3likF primers. The PCR
products were subsequently digested with BamHI and
KpnI And the purified fragments were cloned into pQE30
plasmid downstream of the 6XHis tag (all restriction sites
are underlined).
pET 303/CT His –RC-1
The sense and antisense DNA fragments of 102 bases
including the sequence of cleaved XbaI and XhoI restric-
tion sites were chemically synthesized and hybridized.
The double stranded DNA fragment was cloned directly
into pET 303/CT His vector and transformed into E.
coli.
Protein production in E. coli
The Escherichia coli XL1-Blue strain (Promega, USA)
was transformed with pQE30-NS2B (G4-T-G4) NS3pro
and pET-RC-1. The recombinant E. coli was inocula-
ted in Luria-Bertani liquid medium (1% tryptone, 1%
NaCl, 0.5% yeast extract w/v, pH 7.0) supplemented with
100 mg/L ampicillin and cultured overnight at 37°C. In
general, 10 ml of overnight-grown culture was added to
1000 ml of culture medium and incubated with shaking
at 37°C until the optical density at 600 nm reached 0.5.
Isopropylthio-β-D-galactoside (IPTG) was then added to
the culture medium at a final concentration of 0.5 mM
to induce protein expression and further incubation was
applied for another 5 hrs at 37°C in a shaking incubator.
Bacterial cells were harvested by centrifugation at
4000 rpm for 15 min at 4°C.
Protein purification
The recombinant NS2B-NS3pro and RC-1 were pro-
duced as soluble proteins and purified using His Gravi-
Trap™ Flow precharged Ni Sepharose™ 6 Fast column
(Amersham Biosciences, USA) according to the manu-
facturer’s instructions. In brief, the column was equili-
brated with phosphate buffer (20 mM sodium phosphate
buffer and 500 mM NaCl, pH 7.4). The sample was loaded
into the column and the column was washed with binding
buffer (phosphate buffer containing 20 mM imidazole, pH
7.4). The recombinant protein was eluted with elution
buffer (phosphate buffer containing 200 mM imidazole,
pH 7.4).
Refolding of recombinant RC-1
The mis-folded recombinant RC-1 was refolded as pre-
viously described [22]. In brief, urea was added to the
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purified RC-1 to a final concentration of 2 M and the
pH was adjusted to 12.5. Then, disulphide bonds were
reduced by 5 mM of β-mercaptoethanol and incubated
at room temperature for 30 min with stirring. The de-
natured and reduced RC-1 was diluted to a final con-
centration of 0.01 mg/ml with ice-cold refolding buffer
(100 mM Tris–HCl, 1 mM EDTA, 10% glycerol,
250 mM L-Arginine, 1 mM reduced Glutathione and
0.5 mM oxidized Glutathione (pH 12.5)). Protein sample
was loaded into a dialysis tube and the dialysis was car-
ried out overnight against 200 volumes of 100 mM
Tris–HCl, pH 10 to eliminate the residuals of urea and
β-mercaptoethanol. Overnight incubation of peptide sam-
ples at 4°C was performed before the refolded RC-1 was
concentrated to 1 mg/ml by Vivaspin concentrating 50 ml
tubes with a 3,000 MW cut-off membrane (Sartorius,
Germany). The pH was adjusted to 8.0 and the linker
and 6XHis tag were eliminated after digestion with Factor
Xa and passing the peptide through a Ni-affinity column.
Antimicrobial activity of RC-1
The disc diffusion susceptibility test was used to evaluate
antimicrobial activity of the recombinant RC-1. The
samples of recombinant RC-1 before and after refolding
applications (100 μg/ml) were dropped onto a filter paper
discs (0.1 mg/ml) and left to dry at room temperature.
Then, the filters paper discs placed on an E. coli-inocu-
lated Mueller-Hinton agar and a Saccharomyces cerevisiae
inoculated yeast extract peptone dextrose (YPD) agar pla-
tes. Both E. coli and yeast inoculated plates were inocu-
lated for 16 hrs at 35°C and 30°C, respectively.
Protease assay
The bioassay used in this study was published by Rothan
and co-workers [23]. In brief, endpoint reaction mixtures
with total volume of 200 μl were prepared consisted of
20 μM fluorogenic peptide substrate (Boc-Gly-Arg-Arg-
AMC), 2 μM of recombinant NS2B-NS3pro, with or
without RC-1 of varying concentrations, buffered at pH
8.5 with 200 mM Tris–HCl. The RC-1 was initially pre-
pared in Tris–HCl buffer and assayed at five different
concentrations, ranging from 9.3 - 150 μM. Three types
of reactions which are buffer, buffer with enzyme and
buffer with enzyme and different concentrations of RC-
1were incubated at 28°C, 37°C and 40°C for 30 minutes.
Subsequently, the substrate was added to each reaction
mixture and incubated at same temperatures for another
30 minutes. Measurements were performed in triplicates
using Tecan Infinite M200 Pro fluorescence spectropho-
tometer. Substrate cleavage was normalized against buf-
fer only (control) and optimized at the emission at
440 nm upon excitation at 350 nm. The readings were
then used for calculating Km values of peptide substrate
and IC50 values of peptide inhibitors using non-linear
regression models in GraphPad Prism 5.0 software as
previously described [24].
Maximum non-toxic dose test (MNTD)
Vero cells were seeded at 1 × 104 cells per well in triplicate
in 96 well plates and propagated at optimal conditions
(37°C, 5% CO2 in humidified incubator). Recombinant
RC-1 was diluted to serial concentrations (37.5, 75, 100,
125, 150 and 175 μM) with DMEM media supplemented
with 2% FBS. Each dilution was tested in triplicate. Two
control wells were included in each experiment: culture
medium without RC-1 and culture medium with different
concentrations of the RC-1 in the absence of cells to
subtract the background value of RC-1 in the culture
medium. The cell cultures were analyzed at 24, 48
and 72 hours using Non-Radioactive Cell Proliferation
assay (Promega, USA) according to the manufacturer’s
instructions.
Treatment of DENV-2 infected cells with recombinant RC-1
Three independent experiments were carried out for pre,
simultaneous and post-infection treatments with RC-1 at
24, 48 and 72 hrs of each infection in triplicates. Vero cells
were grown in a 24-well tissue culture plate (1 × 105 cells/
well), incubated 24 hrs under optimal conditions and
infected with DENV-2 (MOI of 2). For pre-treatment in-
fection, 150 μM of RC-1 was added to the cells before
virus inoculation and incubated for 24 hrs. Afterwards,
DENV-2 supernatant was added, followed by incubation
for 1 hr with gentle shaking every 10 min for optimal virus
to cells contact. The virus supernatant was removed, and
the cells were washed twice with fresh serum-free DMEM
media to remove residual virus. New complete DMEM
media were added and the cultures were incubated for 24,
48 and 72 hrs at 37°C, supplemented with 5% CO2. Same
applications were used for simultaneous treatment infec-
tion except the peptide was mixed with the virus super-
natant and incubated at 37°C for 1 h, and then inoculated
onto Vero cells. The post-treatment infection was carried
out after inoculation of Vero cells with DENV-2 and the
complete DMEM medium was added containing the RC-
1. Then, the cultures were incubated for 24, 48 and 72 hrs
at 37°C and 5% CO2 with three wells of infected cells in
each experiment were kept without RC-1 as controls. Cel-
lular supernatants were collected and stored at −80°C for
viral quantification using real time PCR.
Dengue virus quantification by Real time PCR
For quantification of copy number of DENV-2 RNA, the
standard curve was generated by 10-fold serial dilution
of known copies of DENV-2 RNA. Viral RNA was ex-
tracted from culture supernatant using QIAmp viral
RNA mini kit (Qiagen, Germany) according to the man-
ufacturer’s instructions. A fragment located at the 5'UTR
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region of the virus genome was used to generate the pri-
mers. One-step RT-PCR using SyBr Green Master Kit
(Qiagen, Germany) was used to conduct absolute quan-
tification using ABI7300 machine from Applied Biosys-
tems (Foster City, CA). The PCR profile was 1 cycle of
50°C for 2 min, 1 cycle of 95°C for 10 min, 40 cycles of
10 sec denaturation at 95°C, 20 sec annealing at 57.7°C
with a single fluorescence emission measurement and
30 sec extension at 72°C, followed by 5 min at 72°C for
final extension. Dissociation curve analysis was added to
the end of each run. Results were analyzed using the
company's Sequence Detection Software Version 1.3.
Statistical analysis
All assays (Protease assay, Cytotoxicity assay, quantifica-
tion of viral RNA by RT-qPCR) were done in triplicates.
All statistical analyses were performed using GraphPad
Prism version 5.01 (GraphPad Software, San Diego, CA).
P values < 0.05 were considered significant. Error bars
are expressed as ± SD.
Results
Production of recombinant RC-1 and NS2B-NS3pro in
E. coli
Our aim was to produce RC-1 in recombinant form in
E. coli as a cost-effective expression system. In general,
short peptides can be produced in a soluble form in E.
coli. However, it is often challenging to have correct di-
sulphide bond formation in cysteine rich peptides. We
have produced RC-1 as a soluble recombinant peptide
fused with ten amino acids linker followed by a 6XHis
tag (Figure 1A). However, the product was biologically
inactive due to the peptide mis-folding. The main chal-
lenge was to regenerate the activity of recombinant
RC-1 with correct refolding of the peptide by appropri-
ate reformation of the three disulphide bonds (Cys3-
Cys16, Cys5-Cys14 and Cys7-Cys12). Thus, this required
the reduction of all of mis-formed disulphide bonds by
the action of β-mercaptoethanol before the refolding
was carried out. Subsequently, the diluted basic envi-
ronment was applied to allow the formation of intra-
molecules disulphide bonds and reduction in the forma-
tion of inter-molecules disulphide bonds. We used ten
amino acids linker to avoid any interaction between the
6XHis tag and disulphide bonds. To test the activity
of RC-1 in inhibiting the NS2B-NS3pro, we produced
NS2B-NS3pro in E. coli as a single-chain peptide. Nine
amino acids linker was used to join NS2B with NS3pro
downstream of the 6XHis tag sequence (Figure 1B). The
recombinant proteins were detected by SDS-PAGE and
purified using Ni-affinity column (Figure 1C and D). To
validate the functionality of the refolded RC-1, we tested
Figure 1 Production of recombinant RC-1 and dengue NS2B-NS3pro by E. coli. The sequence of RC-1 was linked by 10 amino acids to a
6XHis tag in pET 303/CT His vector. Factor Xa recognition sequence was inserted to cleave both the linker and 6XHis tag after purification.
(A). The NS2B unit of dengue protease was linked to the NS3 by 9 amino acids and the entire DNA fragment was cloned into pQE30 vector
downstream of a 6XHis tag (B). The recombinant E. coli were cultured in Luria-Bertani liquid medium and induced with Isopropylthio-β-D-
galactoside (IPTG) to produce recombinant RC-1 (C, L1 before induction and L2 after induction) and the same procedure was applied to produce
recombinant NS2B-NS3pro. The recombinant RC-1 and NS2B-NS3pro were purified by Ni-affinity column (D, L1 purified dengue protease,
L2 NS2B-NS3pro before purification, L3 purified RC-1 and L4 purified RC-1 after refolding).
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for its antimicrobial activity against E. coli and yeast. It
was found to exhibit antimicrobial activity compared to
the inactive mis-folded form (Figure 2A and B).
The inhibitory potential of RC-1 against Dengue protease
Dengue virus has the ability to propagate at different
temperatures starting from mosquito temperature (28°C),
normal human temperature (37°C) and at temperature of
human with dengue fever (40°C). Therefore, we carefully
studied the activity of NS2B-NS3pro at 28°C, 37°C and
40°C in the presence or absence of recombinant RC-1
peptide. The ability of NS2B-NS3pro to cleave the fluoro-
genic peptide substrate was variable at different tempera-
tures. The highest activity was observed at 28°C and
lowest activity was at 40°C while the activity at 37°C was
in mid-range (Figure 3). The inhibition profile of RC-1
was variable at different temperatures (Figure 4). The
results showed that at 28°C, RC-1 exhibited 100% inhi-
bition of NS2B-NS3pro activity at the concentration of
120 μM. Similarly, a complete inhibition was observed at
100 μM and 37.5 μM at 37°C and at 40°C, respectively.
The lowest 50% inhibitory concentration (IC50 value) of
RC-1 was observed at 40°C (14.1 ± 1.2 μM) and the high-
est IC50 at 28°C (46.1 ± 1.7 μM) whilst at 37°C, the IC50 of
RC-1 was 21.4 ± 1.6 μM.
The inhibitory potential of RC-1 against dengue virus
replication in Vero cells
The maximum non-toxic dose (MNTD) of RC-1 con-
centration in Vero cells was found to be 150 μM for
all of the three incubation periods, 24, 48 and 72 hrs
(Figure 5A). This concentration of RC-1 was used in pre,
simultaneous and post-infection treatment modes in
Vero cells infected with DENV-2 at 24, 48 and 72 hrs.
RNA of DENV-2 was extracted from RC-1 treated and
control cells and quantified by real-time PCR. The results
showed that the highest percentage of reduction in total
viral RNA copies was observed at 24 hrs (45.5% ± 4.2),
48 hrs (70% ± 6.3) and 72 hrs (85% ± 7.1) for the simultan-
eous treatment mode compared to pre and post-treatment.
Furthermore, there was a moderate reduction in viral repli-
cation at pre-treatments mode after 48 hrs (40%) and
Figure 2 Antimicrobial activity of recombinant RC-1 after refolding. Each sample of RC-1 before and after refolding (0.1 mg/ml) was
dropped on filter papers discs and left to dry at room temperature. The dry filter paper discs were placed on E. coli and yeast-inoculated
antibiotic-free Mueller-Hinton-gar and YPD-agar plates respectively and incubated overnight at 37°C (E. coli) or 30°C (yeast). Recombinant RC-1
exhibited antimicrobial activity against E. coli (A) and yeast (Saccharomyces cerevisiae) (B) compared to mis-folded form and control plates
(column buffer) as exhibited by the presence of a clear circular zone in the agar plate.
Figure 3 The activity of dengue NS2B-NS3pro to cleave the
fluorogenic peptide substrate at different temperature
conditions. The enzyme kinetic assay was carried out to evaluate
dengue NS2B-NS3pro activity at temperature of mosquitoes (28°C),
humans (37°C) and humans with severe dengue fever (40°C). Serial
concentrations of the substrate peptide were used to assess the
activity of recombinant DENV-2 protease. Triplicates were performed
for all experiments and the relative fluorescence units (rfu) were
measured using Tecan Infinite M200 Pro fluorescence
spectrophotometer. Substrate cleavage was optimized at the
emission at 440 nm upon excitation at 350 nm. After normalization
of the results with the substrate incubated at same conditions, the
highest activity of recombinant NS2B-NS3pro was observed at 28°C
and lowest activity was at 40°C.
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72 hrs (38%) and post-treatment after 48 hrs (30%) and
72 hrs (45%) (Figure 5B).
Discussion
We conducted this study to evaluate the effect of RC-1,
a cationic cyclic peptide on the activity of dengue prote-
ase as a target to inhibit replication of dengue virus. The
RC-1 was produced inexpensively as a soluble recombin-
ant peptide in E. coli and the tri-disulphide bonds were
correctly reformed in alkaline and diluted environment.
It has been found that the activity of cyclic RC-1 is
3-fold more potent than the open chain analogue, indi-
cating the disulphide bonds have a crucial role in its sta-
bility and functionality [19]. Furthermore, this peptide
is able to provide long-lasting protection against viral
infection since its analogues do not exhibit pro-infla-
mmatory reactions, haemolytic activity or cellular tox-
icity [25,26]. Thus, the recombinant RC-1 peptide can
be considered as a potential candidate for development
of a successful drug to treat dengue and other infectious
diseases.
The activity of recombinant NS2B-NS3pro was mea-
sured by a fluorescence-labelled substrate as previously
described [23,27]. The function of dengue protease de-
pends on the binding between NS2B and NS3pro to
form NS2B-NS3pro complex. It has been found that this
enzyme has an essential role in dengue virus replica-
tion through the cleavage of the viral polyprotein [12].
Therefore, blocking the active site or the interaction be-
tween the two subunits could directly disturb the activity
of dengue protease and hence virus replication in host
cells. Previous studies indicated that disulphide cyclic
peptides have inhibition potential against dengue virus
protease at different temperatures [15,16]. It has been
known that the negatively-charged NS2B is positioned in
a positive charged cleft on NS3pro [28]. Therefore it is
possible that the RC-1, which is a cationic peptide, may
inhibit the activity of dengue protease via direct interac-
tions with the active site or by blocking the binding be-
tween the two subunits of the protease complex. Further
studies are necessitated to elucidate the interaction be-
tween RC-1 and dengue protease that may have led to
the inhibition of its activity.
Chemically synthesised RC-1 and its analogues by
solid-phase peptide synthesis have been commonly used
in many studies to determine its inhibitory potential
against viral replication such as HIV [29], avian influenza
H5N1 virus [30], Herpes Simplex Virus [31] and other
microorganisms such as Bacillus anthracis [32] and Sta-
phylococcus aureus [25]. However, to the best of our
knowledge, there are no studies reported on the produc-
tion of the RC-1 peptide in recombinant form in E. coli.
Nonetheless, retrocyclins expression has been reported
in other expression systems such as plant [33] and mam-
malian cells [30]. Unlike E. coli, these expression systems
cannot be scaled up for larger production of recombinant
Figure 4 The inhibition potential of RC-1 against the activity of DENV-2 NS2B-NS3pro. End point protease inhibition assay was carried out
to evaluate the inhibitory potential of RC-1 against the protease’s ability to cleave a fluorogenic peptide substrate (Boc-Gly-Arg-Arg-AMC). The
reaction mixtures consisted of 20 μM substrate, 2 μM of enzyme, with or without RC-1 of varying concentrations incubated at 28°C, 37°C or 40°C
for 30 minutes. The results were normalized with the substrate alone and substrate with protease incubated at same temperatures. The inhibition
was found to be temperature dependent with the highest concentration (120 μM) at 28°C and the lowest concentration (37.5 μM ) at 40°C.
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protein in a cost-effective manner. We found that E. coli
was able to produce soluble inactive recombinant RC-1
and the activity can be retrieved after refolding steps. The
main challenge in maintaining the activity of recombinant
RC-1 was in the reformation of the inter-molecular tri-
disulphide bonds in its native order and to reduce intra-
molecular disulphide bonds, which were addressed in this
study. We have reported that the optimal refolding of
cysteine rich proteins can be achieved in an alkaline and
diluted environment in the presence of redox agents,
which is in agreement with other studies [22]. The intra-
molecular disulphide bonds were reduced after the dilu-
tion of the samples to 0.01 mg/ml in the presence of gly-
cerol. In this study, the correct refolding was confirmed
by the assessment of the RC-1 anti-microbial activity
against E.coli and yeast (Saccharomyces cerevisiae).
Dengue protease exhibited highest activity at the tem-
perature of mosquitoes (28°C) compared to the tempe-
rature of humans (37°C) and humans with severe dengue
fever (40°C). Overall, this suggests that despite the low
copy number of virus that is delivered by a mosquito bite,
the viral virulence is very high. The complete inhibition of
dengue protease had been achieved by different concen-
trations of RC-1 depending on the temperatures as ex-
pressed by various IC50 values. These are crucial factors to
be taken into consideration in developing the RC-1 as an
inhibitor-like drug in order to understand the drug stabil-
ity and dose requirements at different stages of infection.
In this study, the inhibition potential of RC-1 is tem-
perature dependent (IC50 21.4 μM at 37°C and 14.1 μM
at 40°C) which is important to develop the RC-1 as an
inhibitor-like drug to treat dengue. The inhibition poten-
tial of RC-1 is in the same range with other chemical com-
pounds reported recently. These compounds inhibited
recombinant dengue NS2B-NS3pro with IC50 of 15.4, 20.4
and 27.0 μM [34].
It has been known that the compound toxicity could
hinder the development of drugs against dengue virus.
Figure 5 The percentage of viral reduction in Vero cells after different treatments with RC-1. (A) RC-1 was diluted to various
concentrations (37.5, 75, 100, 125, 150 and 175 μM) with DMEM media supplemented with 2 % FBS and added to the cell culture. The viability of
cells was analyzed at 24, 48 and 72 hrs using Non-Radioactive Cell Proliferation assay. (B) The cells were grown under the optimal conditions and
infected with DENV-2 at the MOI of 2. The MNTD of RC-1 (150 μM) was used to treat infected Vero cells and the results were normalized with
infected cells without RC-1 as controls. Pre, simultaneous and post-infection treatments with RC-1 were applied at 24, 48 and 72 hrs of each
infection. The percentage of inhibition was the highest for simultaneous treatment compared to pre and post-treatment. (Two way ANOVA was
used with Bonferroni post-test, P < 0.0001).
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In this study, recombinant RC-1 exhibited low cellular
toxicity in Vero cells (150 μM) and has shown no no-
ticeable cellular morphological abnormalities. In addi-
tion, it has been reported to have neither haemolytic
activity nor cytotoxicity in different cell lines at up to a
concentration of 500 μg/ml (250 μM) [26]. In addition,
retrocyclins had no toxicity against human nasal epithe-
lia at a concentration up to 200 μM, and did not induce
any pro-inflammatory response in these cells [25]. In
this study, the maximum non-toxic dose was used to
treat the Vero cells infected with DENV-2. The viral rep-
lication was significantly declined after treatment with
recombinant RC-1 at pre, simultaneous and post infec-
tion treatment modes. The highest significant reduction
in dengue virus RNA replication was observed after sim-
ultaneous treatment of infected Vero cells. Therefore, it
is possible that the recombinant RC-1 has an ability to
reduce viral RNA replication by disturbing the activity
of NS2B-NS3pro. Nevertheless, other possibilities of
additional effects of RC-1 on Vero cells that may lead
to reduction in viral RNA should be also taken in
consideration.
Conclusion
We successfully produced bioactive recombinant RC-1
in E. coli as a cost-effective expression system that can
be developed for large-scale production. The recombin-
ant RC-1 was able to inhibit dengue protease that led to
reduction of dengue virus in Vero cells. These findings
may have its importance in the development of thera-
peutic agent especially against dengue infection.
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